Xeris Biopharma Holdings (XERS) Total Debt Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) Total Debt Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -3.69% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 37.49% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -2.48% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 4.38% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -6.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 41.53% |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | 44.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.71% |
| Mar 31, 2026 | -8.48% |
| Dec 31, 2025 | -10.87% |
| Sep 30, 2025 | -5.11% |
| Jun 30, 2025 | -5.32% |
| Mar 31, 2025 | 4.78% |
| Dec 31, 2024 | 29.48% |
| Sep 30, 2024 | 11.23% |
| Jun 30, 2024 | 12.73% |
| Mar 31, 2024 | 13.88% |
| Dec 31, 2023 | 2.06% |
| Sep 30, 2023 | 50.13% |
| Jun 30, 2023 | 48.35% |
| Mar 31, 2023 | 47.18% |
| Dec 31, 2022 | 112.42% |
| Sep 30, 2022 | 57.91% |
| Dec 31, 2021 | 1.20% |